SPIMACO’s H1 net profit rises 20%

06/08/2017 Argaam Exclusive

View other reports

Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) reported a net profit of SAR 153.4 million for the first half of 2017, a 19.9 percent year-on-year (YoY) increase, thanks to a 13.3 percent decline in sales and marketing expenses.

The company also recorded SAR 46.1 million gains from selling securities.

Financials (M)

Item	6m 2016	6m 2017	Change‬
Revenues	661.75	697.74	5.4 %
Gross Income	377.84	368.71	(2.4 %)
Operating Income	80.72	99.43	23.2 %
Net Income	128.53	147.78	15.0 %
Average Shares	120.00	120.00	-
Earnings Per Share before unusual items (Riyals)	0.94	0.85	(10.1 %)
EPS (Riyal)	1.07	1.23	15.0 %

Net profit for the second quarter grew by 35.8 percent YoY to SAR 53.4 million, backed by lower selling, general and administrative expenses.

When compared to the previous quarter, the pharmaceutical producer’s net profit declined by 46.6 percent, due to a drop in gross profit and sales despite lower operating expenses.

Current Quarter Comparison (M)

Compared With The

Item	Q2 2016	Q2 2017	Change‬
Revenues	339.54	304.63	(10.3 %)
Gross Income	183.58	156.13	(15.0 %)
Operating Income	27.50	49.40	79.6 %
Net Income	39.61	46.56	17.5 %
Average Shares	120.00	120.00	-
Earnings Per Share before unusual items (Riyal)	0.33	0.39	17.5 %
EPS (Riyal)	0.33	0.39	17.5 %

Item	Q1 2017	Q2 2017	Change‬
Revenues	393.10	304.63	(22.5 %)
Gross Income	212.58	156.13	(26.6 %)
Operating Income	50.03	49.40	(1.3 %)
Net Income	101.22	46.56	(54.0 %)
Average Shares	120.00	120.00	-
Earnings Per Share before unusual items (Riyal)	0.46	0.39	(15.5 %)
EPS (Riyal)	0.84	0.39	(54.0 %)

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2008	220.58	8.5 %	99.57	9.4 %	41.61	4.0 %
Q2 2008	211.66	1.1 %	74.78	12.5 %	11.06	253.2 %
Q3 2008	145.45	(2.6 %)	74.34	11.2 %	21.36	(11.5 %)
Q4 2008	294.26	24.8 %	114.28	11.7 %	38.48	26.3 %
2008	871.94	9.3 %	362.97	11.1 %	112.51	15.1 %
Q1 2009	257.88	16.9 %	108.57	9.0 %	46.06	10.7 %
Q2 2009	229.00	8.2 %	81.53	9.0 %	16.76	51.6 %
Q3 2009	171.15	17.7 %	72.49	(2.5 %)	18.81	(11.9 %)
Q4 2009	292.71	(0.5 %)	157.00	37.4 %	64.46	67.5 %
2009	950.74	9.0 %	419.59	15.6 %	146.09	29.8 %
Q1 2010	274.33	6.4 %	118.90	9.5 %	52.94	14.9 %
Q2 2010	252.34	10.2 %	100.50	23.3 %	21.50	28.3 %
Q3 2010	191.40	11.8 %	85.88	18.5 %	20.68	9.9 %
Q4 2010	319.57	9.2 %	181.12	15.4 %	70.70	9.7 %
2010	1,037.64	9.1 %	486.40	15.9 %	165.82	13.5 %
Q1 2011	252.08	(8.1 %)	123.51	3.9 %	49.79	(6.0 %)
Q2 2011	292.08	15.7 %	123.61	23.0 %	30.59	42.3 %
Q3 2011	209.24	9.3 %	106.76	24.3 %	33.19	60.5 %
Q4 2011	375.82	17.6 %	206.69	14.1 %	76.86	8.7 %
2011	1,129.22	8.8 %	560.57	15.2 %	191.36	15.4 %
Q1 2012	303.14	20.3 %	153.21	24.0 %	63.10	26.7 %
Q2 2012	286.64	(1.9 %)	140.91	14.0 %	34.78	13.7 %
Q3 2012	227.40	8.7 %	113.28	6.1 %	39.61	19.3 %
Q4 2012	365.97	(2.6 %)	211.16	2.2 %	63.57	(17.3 %)
2012	1,183.15	4.8 %	618.56	10.3 %	201.06	5.1 %
Q1 2013	361.37	19.2 %	184.62	20.5 %	70.64	11.9 %
Q2 2013	344.22	20.1 %	179.12	27.1 %	40.64	16.8 %
Q3 2013	222.91	(2.0 %)	118.64	4.7 %	35.37	(10.7 %)
Q4 2013	382.01	4.4 %	226.14	7.1 %	60.19	(5.3 %)
2013	1,310.50	10.8 %	708.52	14.5 %	205.58	2.2 %
Q1 2014	405.21	12.1 %	206.72	12.0 %	76.05	7.7 %
Q2 2014	371.14	7.8 %	193.14	7.8 %	44.90	10.5 %
Q3 2014	266.02	19.3 %	134.45	13.3 %	31.26	(11.6 %)
Q4 2014	431.06	12.8 %	261.80	15.8 %	90.22	49.9 %
2014	1,470.19	12.2 %	794.54	12.1 %	241.94	17.7 %
Q1 2015	432.20	6.7 %	225.86	9.3 %	91.35	20.1 %
Q2 2015	435.80	17.4 %	210.95	9.2 %	48.02	6.9 %
Q3 2015	308.27	15.9 %	131.32	(2.3 %)	24.69	(21.0 %)
Q4 2015	520.38	20.7 %	266.38	1.7 %	101.91	13.0 %
2015	1,705.05	16.0 %	848.60	6.8 %	262.04	8.3 %
Q1 2016	322.20	(25.4 %)	194.26	(14.0 %)	53.22	(41.7 %)
Q2 2016	339.54	(22.1 %)	183.58	(13.0 %)	27.50	(42.7 %)
Q3 2016	257.21	(16.6 %)	140.54	7.0 %	9.14	(63.0 %)
Q4 2016	339.59	(34.7 %)	194.16	(27.1 %)	13.46	(86.8 %)
2016	1,258.55	(26.2 %)	712.54	(16.0 %)	103.32	(60.6 %)
Q1 2017	393.10	22.0 %	212.58	9.4 %	50.03	(6.0 %)
Q2 2017	304.63	(10.3 %)	156.13	(15.0 %)	49.40	79.6 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2007	797.75	9.6 %	326.62	5.9 %	97.74	(9.6 %)
2008	871.94	9.3 %	362.97	11.1 %	112.51	15.1 %
2009	950.74	9.0 %	419.59	15.6 %	146.09	29.8 %
2010	1,037.64	9.1 %	486.40	15.9 %	165.82	13.5 %
2011	1,129.22	8.8 %	560.57	15.2 %	191.36	15.4 %
2012	1,183.15	4.8 %	618.56	10.3 %	201.06	5.1 %
2013	1,310.50	10.8 %	708.52	14.5 %	205.58	2.2 %
2014	1,470.19	12.2 %	794.54	12.1 %	241.94	17.7 %
2015	1,705.05	16.0 %	848.60	6.8 %	262.04	8.3 %
2016	1,258.55	(26.2 %)	712.54	(16.0 %)	103.32	(60.6 %)

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS(Riyal)
Q1 2008	40.93	3.6 %	0.40	-	40.93	0.40
Q2 2008	34.24	51.7 %	0.34	(0.45)	34.70	0.34
Q3 2008	15.62	(41.1 %)	0.15	(3.69)	19.83	0.20
Q4 2008	37.48	12.6 %	0.37	-	37.48	0.37
2008	128.27	5.2 %	1.26	(3.89)	132.16	1.30
Q1 2009	42.69	4.3 %	0.42	(0.18)	42.87	0.42
Q2 2009	37.81	10.4 %	0.37	0.00	37.81	0.37
Q3 2009	15.84	1.4 %	0.16	0.00	15.84	0.16
Q4 2009	58.48	56.0 %	0.58	(3.12)	61.60	0.61
2009	154.81	20.7 %	1.53	(3.30)	158.11	1.56
Q1 2010	45.32	6.2 %	0.38	(3.24)	48.56	0.40
Q2 2010	43.09	14.0 %	0.36	-	43.09	0.36
Q3 2010	18.07	14.1 %	0.15	-	18.07	0.15
Q4 2010	70.04	19.8 %	0.58	-	70.04	0.58
2010	176.52	14.0 %	1.47	(3.24)	179.76	1.50
Q1 2011	45.71	0.9 %	0.38	-	45.71	0.38
Q2 2011	60.75	41.0 %	0.51	-	60.75	0.51
Q3 2011	29.75	64.6 %	0.25	-	29.75	0.25
Q4 2011	74.06	5.7 %	0.62	-	74.06	0.62
2011	211.44	19.8 %	1.76	-	211.44	1.76
Q1 2012	56.45	23.5 %	0.47	-	56.45	0.47
Q2 2012	90.14	48.4 %	0.75	-	90.14	0.75
Q3 2012	32.33	8.7 %	0.27	-	32.33	0.27
Q4 2012	53.73	(27.5 %)	0.45	-	53.73	0.45
2012	232.65	10.0 %	1.94	-	232.65	1.94
Q1 2013	63.15	11.9 %	0.53	-	63.15	0.53
Q2 2013	113.71	26.1 %	0.95	-	113.71	0.95
Q3 2013	34.19	5.8 %	0.28	-	34.19	0.28
Q4 2013	57.01	6.1 %	0.48	-	57.01	0.48
2013	266.82	14.7 %	2.22	-	266.82	2.22
Q1 2014	91.17	44.4 %	0.76	-	91.17	0.76
Q2 2014	97.72	(14.1 %)	0.81	-	97.72	0.81
Q3 2014	36.69	7.3 %	0.31	-	36.69	0.31
Q4 2014	91.29	60.1 %	0.76	-	91.29	0.76
2014	316.85	18.8 %	2.64	-	316.85	2.64
Q1 2015	99.39	9.0 %	0.83	-	99.39	0.83
Q2 2015	237.63	143.2 %	1.98	151.31	86.32	0.72
Q3 2015	29.16	(20.5 %)	0.24	-	29.16	0.24
Q4 2015	(9.12)	(110.0 %)	(0.08)	(118.50)	109.38	0.91
2015	357.05	12.7 %	2.98	32.81	324.25	2.70
Q1 2016	88.91	(10.5 %)	0.74	15.46	73.45	0.61
Q2 2016	39.61	(83.3 %)	0.33	-	39.61	0.33
Q3 2016	4.76	(83.7 %)	0.04	-	4.76	0.04
Q4 2016	143.48	1673.8 %	1.20	189.84	(46.36)	(0.39)
2016	276.76	(22.5 %)	2.31	205.30	71.46	0.60
Q1 2017	101.22	13.8 %	0.84	46.14	55.08	0.46
Q2 2017	46.56	17.5 %	0.39	-	46.56	0.39

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS(Riyal)
2007	121.87	16.0 %	1.20	-	121.87	1.20
2008	128.27	5.2 %	1.26	(3.89)	132.16	1.30
2009	154.81	20.7 %	1.53	(3.30)	158.11	1.56
2010	176.52	14.0 %	1.47	(3.24)	179.76	1.50
2011	211.44	19.8 %	1.76	-	211.44	1.76
2012	232.65	10.0 %	1.94	-	232.65	1.94
2013	266.82	14.7 %	2.22	-	266.82	2.22
2014	316.85	18.8 %	2.64	-	316.85	2.64
2015	357.05	12.7 %	2.98	32.81	324.25	2.70
2016	276.76	(22.5 %)	2.31	205.30	71.46	0.60

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2008	41.13 %	15.70 %	15.13 %
Q2 2008	42.03 %	16.67 %	16.57 %
Q3 2008	43.15 %	16.47 %	15.83 %
Q4 2008	41.63 %	16.30 %	15.25 %
2008	41.63 %	16.30 %	15.16 %
Q1 2009	40.91 %	16.13 %	14.83 %
Q2 2009	40.87 %	16.44 %	14.89 %
Q3 2009	39.57 %	15.73 %	14.07 %
Q4 2009	44.13 %	18.49 %	16.63 %
2009	44.13 %	18.49 %	16.63 %
Q1 2010	44.45 %	18.88 %	16.94 %
Q2 2010	45.32 %	18.93 %	17.07 %
Q3 2010	45.73 %	18.73 %	16.95 %
Q4 2010	46.88 %	18.85 %	17.32 %
2010	46.88 %	18.85 %	17.32 %
Q1 2011	48.36 %	18.99 %	17.42 %
Q2 2011	48.73 %	19.12 %	18.44 %
Q3 2011	49.86 %	19.99 %	19.22 %
Q4 2011	49.64 %	19.57 %	18.62 %
2011	49.64 %	19.65 %	18.72 %
Q1 2012	50.01 %	19.86 %	18.73 %
Q2 2012	51.72 %	20.36 %	21.31 %
Q3 2012	51.47 %	20.54 %	21.21 %
Q4 2012	52.28 %	19.56 %	19.66 %
2012	52.28 %	19.56 %	19.66 %
Q1 2013	52.36 %	19.26 %	19.28 %
Q2 2013	52.98 %	18.87 %	20.24 %
Q3 2013	53.58 %	18.66 %	20.45 %
Q4 2013	54.06 %	18.26 %	20.45 %
2013	54.06 %	18.16 %	20.36 %
Q1 2014	53.95 %	17.92 %	21.86 %
Q2 2014	53.91 %	17.74 %	20.28 %
Q3 2014	53.39 %	16.79 %	19.84 %
Q4 2014	54.03 %	18.15 %	21.50 %
2014	54.04 %	18.15 %	21.55 %
Q1 2015	54.34 %	18.90 %	21.67 %
Q2 2015	53.23 %	18.31 %	20.04 %
Q3 2015	51.63 %	17.40 %	19.05 %
Q4 2015	49.19 %	17.17 %	19.11 %
2015	49.77 %	16.85 %	19.02 %
Q1 2016	50.60 %	15.90 %	18.80 %
Q2 2016	52.04 %	15.52 %	16.88 %
Q3 2016	54.52 %	15.09 %	15.79 %
Q4 2016	56.62 %	10.25 %	5.68 %
2016	56.62 %	10.25 %	5.68 %
Q1 2017	54.97 %	9.67 %	3.99 %
Q2 2017	54.34 %	11.85 %	4.64 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2007	40.94 %	15.79 %	15.28 %
2008	41.63 %	16.30 %	15.16 %
2009	44.13 %	18.49 %	16.63 %
2010	46.88 %	18.85 %	17.32 %
2011	49.64 %	19.65 %	18.72 %
2012	52.28 %	19.56 %	19.66 %
2013	54.06 %	18.16 %	20.36 %
2014	54.04 %	18.15 %	21.55 %
2015	49.77 %	16.85 %	19.02 %
2016	56.62 %	10.25 %	5.68 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2008	45.14 %	22.16 %	18.55 %
Q2 2008	35.33 %	8.71 %	16.39 %
Q3 2008	51.11 %	19.82 %	13.64 %
Q4 2008	38.84 %	15.63 %	12.74 %
Q1 2009	42.10 %	20.70 %	16.62 %
Q2 2009	35.60 %	10.54 %	16.51 %
Q3 2009	42.35 %	15.37 %	9.25 %
Q4 2009	53.64 %	24.60 %	21.04 %
Q1 2010	43.34 %	21.92 %	17.70 %
Q2 2010	39.83 %	11.52 %	17.08 %
Q3 2010	44.87 %	14.68 %	9.44 %
Q4 2010	56.68 %	24.50 %	21.92 %
Q1 2011	49.00 %	22.74 %	18.13 %
Q2 2011	42.32 %	13.00 %	20.80 %
Q3 2011	51.02 %	19.57 %	14.22 %
Q4 2011	55.00 %	22.56 %	19.71 %
Q1 2012	50.54 %	23.32 %	18.62 %
Q2 2012	49.16 %	14.95 %	31.45 %
Q3 2012	49.82 %	20.53 %	14.22 %
Q4 2012	57.70 %	19.47 %	14.68 %
Q1 2013	51.09 %	21.68 %	17.48 %
Q2 2013	52.04 %	14.20 %	33.03 %
Q3 2013	53.22 %	19.34 %	15.34 %
Q4 2013	59.20 %	18.05 %	14.92 %
Q1 2014	51.02 %	20.19 %	22.50 %
Q2 2014	52.04 %	13.80 %	26.33 %
Q3 2014	50.54 %	13.97 %	13.79 %
Q4 2014	60.73 %	22.54 %	21.18 %
Q1 2015	52.26 %	22.70 %	23.00 %
Q2 2015	48.40 %	12.42 %	19.81 %
Q3 2015	42.60 %	9.85 %	9.46 %
Q4 2015	51.19 %	20.88 %	21.02 %
Q1 2016	60.29 %	18.36 %	22.80 %
Q2 2016	54.07 %	9.77 %	11.67 %
Q3 2016	54.64 %	6.30 %	1.85 %
Q4 2016	57.18 %	6.04 %	(13.65 %)
Q1 2017	54.08 %	14.94 %	14.01 %
Q2 2017	51.25 %	19.02 %	15.29 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
Q1 2008	101.51	1.21	1.21	26.83
Q2 2008	101.51	1.33	1.33	27.74
Q3 2008	101.51	1.22	1.27	21.88
Q4 2008	101.51	1.26	1.31	13.76
Q1 2009	101.51	1.28	1.33	14.17
Q2 2009	101.51	1.32	1.36	17.62
Q3 2009	101.51	1.32	1.32	19.72
Q4 2009	101.51	1.53	1.56	21.46
Q1 2010	120.00	1.31	1.36	22.04
Q2 2010	120.00	1.36	1.41	19.98
Q3 2010	120.00	1.37	1.43	21.69
Q4 2010	120.00	1.47	1.50	24.48
Q1 2011	120.00	1.47	1.47	25.41
Q2 2011	120.00	1.62	1.62	27.29
Q3 2011	120.00	1.72	1.72	25.92
Q4 2011	120.00	1.75	1.75	26.50
Q1 2012	120.00	1.84	1.84	30.26
Q2 2012	120.00	2.09	2.09	25.75
Q3 2012	120.00	2.11	2.11	26.24
Q4 2012	120.00	1.94	1.94	25.28
Q1 2013	120.00	1.99	1.99	27.18
Q2 2013	120.00	2.19	2.19	26.14
Q3 2013	120.00	2.21	2.21	27.35
Q4 2013	120.00	2.23	2.23	32.18
Q1 2014	120.00	2.47	2.47	32.96
Q2 2014	120.00	2.33	2.33	33.21
Q3 2014	120.00	2.35	2.35	35.74
Q4 2014	120.00	2.64	2.64	28.75
Q1 2015	120.00	2.71	2.71	27.84
Q2 2015	120.00	3.87	2.61	28.72
Q3 2015	120.00	3.81	2.55	24.87
Q4 2015	120.00	2.98	2.70	22.17
Q1 2016	120.00	2.89	2.49	20.84
Q2 2016	120.00	1.24	2.10	20.49
Q3 2016	120.00	1.03	1.89	20.40
Q4 2016	120.00	2.31	0.60	22.59
Q1 2017	120.00	2.41	0.44	23.27
Q2 2017	120.00	2.47	0.50	21.52

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
2007	101.51	1.20	1.20	28.41
2008	101.51	1.26	1.30	13.76
2009	101.51	1.53	1.56	21.46
2010	120.00	1.47	1.50	24.48
2011	120.00	1.76	1.76	26.50
2012	120.00	1.94	1.94	25.28
2013	120.00	2.22	2.22	32.18
2014	120.00	2.64	2.64	28.75
2015	120.00	2.98	2.70	22.17
2016	120.00	2.31	0.60	22.59

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Recurring P/E	Price/book
Q1 2008	27.68	27.68	1.25
Q2 2008	26.79	26.70	1.28
Q3 2008	20.49	19.74	1.14
Q4 2008	12.99	12.53	1.19
Q1 2009	14.92	14.39	1.35
Q2 2009	17.20	16.65	1.28
Q3 2009	18.29	18.26	1.22
Q4 2009	15.25	14.94	1.08
Q1 2010	16.69	16.04	0.99
Q2 2010	14.70	14.15	1.00
Q3 2010	14.64	14.10	0.93
Q4 2010	15.82	15.53	0.95
Q1 2011	17.65	17.65	1.02
Q2 2011	15.68	15.68	0.93
Q3 2011	14.41	14.41	0.96
Q4 2011	15.03	15.03	0.99
Q1 2012	17.92	17.92	1.09
Q2 2012	12.56	12.56	1.02
Q3 2012	13.70	13.70	1.10
Q4 2012	14.74	14.74	1.13
Q1 2013	13.60	13.60	1.00
Q2 2013	15.51	15.51	1.30
Q3 2013	15.70	15.70	1.27
Q4 2013	19.02	19.02	1.32
Q1 2014	19.07	19.07	1.43
Q2 2014	19.29	19.29	1.36
Q3 2014	21.41	21.41	1.41
Q4 2014	12.89	12.89	1.18
Q1 2015	14.78	14.78	1.44
Q2 2015	11.59	17.18	1.56
Q3 2015	9.46	14.14	1.45
Q4 2015	11.16	12.29	1.50
Q1 2016	11.15	12.96	1.55
Q2 2016	29.96	17.69	1.81
Q3 2016	30.18	16.49	1.53
Q4 2016	17.72	68.63	1.81
Q1 2017	15.03	81.82	1.56
Q2 2017	14.32	70.59	1.64

Period	P/E	Recurring P/E	Price/book
2007	33.83	33.83	1.43
2008	12.99	12.60	1.19
2009	15.25	14.94	1.08
2010	15.82	15.53	0.95
2011	14.95	14.95	0.99
2012	14.74	14.74	1.13
2013	19.11	19.11	1.32
2014	12.89	12.89	1.18
2015	11.16	12.29	1.50
2016	17.72	68.63	1.81

Business Segments (Million)

Compared With The

Period	Medical & Pharmaceutical production segment	Investment activity	Eliminations
Q1 2008	220.58	-	-
Q2 2008	211.66	-	-
Q3 2008	145.45	-	-
Q4 2008	294.25	-	-
Q1 2009	257.88	-	-
Q2 2009	229.00	-	-
Q3 2009	171.15	-	-
Q4 2009	292.71	-	-
Q1 2010	274.33	-	-
Q2 2010	252.34	-	-
Q3 2010	191.41	-	-
Q4 2010	319.57	-	-
Q1 2011	252.08	-	-
Q2 2011	292.08	-	-
Q3 2011	209.24	-	-
Q4 2011	375.82	-	-
Q1 2012	303.14	-	-
Q2 2012	286.65	-	-
Q3 2012	227.40	-	-
Q4 2012	365.97	-	-
Q1 2013	361.37	-	-
Q2 2013	344.22	-	-
Q3 2013	222.91	-	-
Q4 2013	382.01	-	-
Q1 2014	405.21	-	-
Q2 2014	374.14	-	-
Q3 2014	266.02	-	-
Q4 2014	427.82	-	-
Q1 2015	432.29	14.84	-
Q2 2015	436.99	195.93	-
Q3 2015	308.38	9.55	-
Q4 2015	529.24	-	-
Q1 2016	513.97	25.27	-
Q2 2016	494.92	9.41	-
Q3 2016	100.39	6.23	-
Q4 2016	401.35	247.84	-
Q1 2017	446.00	50.90	(51.45)
Q2 2017	350.01	1.39	(43.30)

Period	Medical & Pharmaceutical production segment	Investment activity	Eliminations
2007	797.75	-	-
2008	871.94	-	-
2009	950.74	-	-
2010	1,037.64	-	-
2011	1,129.22	-	-
2012	1,183.15	-	-
2013	1,310.50	-	-
2014	1,470.19	-	-
2015	1,706.80	115.14	-
2016	1,510.63	288.74	(244.41)

Analysts Estimates (Million)

Item	Profit (Expected)	Profit (Actual)	Change
Average	53.00	46.56

Estimates vs Actual (Million)

Item	Profit (Expected)	Profit (Actual)	Change‬
Hermes	51.00	46.56
HSBC	55.00	46.56

Financial Ratios

	Current
Market Cap (M Riyal)	3,573.60
Enterprise Value (EV) (M Riyal)	4,871.52
Shares Outstanding ((M))	120.00
EPS ( Riyal) (TTM)	0.49
Book Value (BV) ( Riyal)	12.53
Par Value ( Riyal)	10.00
Recurring P/E	More than 100
P/E (TTM)	60.31
Price/book	2.38
Return on Average Assets (%) (TTM)	1.3
Return on Average Equity (%) (TTM)	4.1
EV/adj EBITDA	20.01
EV/Revenues	2.83

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

SPIMACO’s H1 net profit rises 20%

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2017 Q2

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

SPIMACO’s H1 net profit rises 20%

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q2 2017

Revenue by Business Segment (Latest) 2017 Q2

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)